Compare GSK plc (GSK) vs Ulta Beauty Inc (ULTA) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

ULTA Beauty trades at $478.30, up 1.96% today, with a neutral technical signal and strong fundamentals including a 47.45% ROE and 9.36% net margin. Recent earnings beat expectations in Q1 2026, but net cash flow turned negative in 2025. The stock is supported by a loyal customer base and international expansion initiatives, including a new CTO appointment to bolster digital capabilities.

The outlook is positive with a consensus price target of $623.73, implying 30% upside, though risks include competitive pressures and fluctuating cash flows. Analyst sentiment is bullish with 56.5% buy ratings, but investors should monitor margin sustainability and macroeconomic impacts on consumer spending.